Halozyme Therapeutics, Inc. (HALO)

Healthcare · Biotechnology · NASDAQ

Halozyme Therapeutics, Inc. (HALO) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $13.07B, a trailing price-to-earnings ratio of 21.5 and a free-cash-flow yield of 2.5%. Over the most recent reported fiscal year, revenue grew 37.5% and free cash flow per share fell 20.4%.

Market cap	$13.07B
Trailing P/E	21.5
FCF yield	2.5%
Revenue growth (YoY)	+37.5%
EPS growth (YoY)	-2.4%
FCF/share growth (YoY)	-20.4%
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

Explore live HALO data on Nama Insights →

Recent Congressional trades

Halozyme Therapeutics, Inc. trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
Gilbert Cisneros	House	Buy	$1,001 - $15,000	Apr 7, 2026
Gilbert Cisneros	House	Sell	$1,001 - $15,000	Apr 7, 2025
Josh Gottheimer	House	Sell	$1,001 - $15,000	Oct 3, 2024
Mark R Warner	Senate	Sell	$500,001 - $1,000,000	—